Skip to main content
. 2017 Apr 9;8(45):79223–79233. doi: 10.18632/oncotarget.16985

Table 6. Sensitivity analysis; assuming treatment dependent DM health state costs - probabilistic.

Trastuzumab No trastuzumab Increment ICER
Costs QALYs Costs QALYs Costs QALYs
Real world scenario € 176,541 13.927 € 315,715 13.097 -€ 139,175 0.830 Dominance
Guideline scenario € 165,256 13.551 € 293,593 12.686 -€ 128,337 0.865 Dominance
Trial scenario € 181,133 14.095 € 357,625 13.103 -€ 176,492 0.993 Dominance